A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Iza-bren
DRUG: Nab-paclitaxel
DRUG: Paclitaxel
DRUG: Capecitabine
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]